LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Elenco Azioni・Incyte Corp

Incyte Corp

Chiusa

SettoreSettore sanitario

100.79 -1.52

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

98.54

Massimo

104.46

Metriche Chiave
By Trading Economics
Entrata	4.1M 303M
Vendite	-234M 1.3B
P/E Media del settore	13.501 49.888
EPS	1.81
Margine di Profitto	23.834
Dipendenti	2,844
EBITDA	-47M 368M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+6.27% upside

Dividendi
By Dow Jones
Utili prossimi	28 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	49M 19B
Apertura precedente	102.31
Chiusura precedente	100.79

Notizie sul Sentiment di mercato

By Acuity

47%

53%

151 / 344 Classifica in Healthcare

Incyte Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 giu 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 giu 2026, 15:41 UTC

I principali Market Mover

American Battery Shares Jump on Energy Department Victory

8 giu 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 giu 2026, 23:37 UTC

Discorsi di Mercato

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 giu 2026, 23:25 UTC

Discorsi di Mercato

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 giu 2026, 23:25 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 giu 2026, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 giu 2026, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Agrees to Buy m3ter

8 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

8 giu 2026, 19:22 UTC

Discorsi di Mercato

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 giu 2026, 19:01 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 giu 2026, 18:52 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

8 giu 2026, 18:52 UTC

Discorsi di Mercato

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 giu 2026, 18:17 UTC

Discorsi di Mercato

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 giu 2026, 17:32 UTC

Discorsi di Mercato

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 giu 2026, 17:29 UTC

Discorsi di Mercato

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 giu 2026, 17:29 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 giu 2026, 16:55 UTC

Acquisizioni, Fusioni, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 giu 2026, 16:54 UTC

Acquisizioni, Fusioni, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 giu 2026, 16:40 UTC

Discorsi di Mercato

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 giu 2026, 16:31 UTC

Discorsi di Mercato

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 giu 2026, 16:27 UTC

Discorsi di Mercato

Mexican Inflation Seen Easing in May -- Market Talk

8 giu 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 giu 2026, 16:03 UTC

Acquisizioni, Fusioni, Takeovers

Orange Bought Stake From Lorca

8 giu 2026, 16:01 UTC

Acquisizioni, Fusioni, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 giu 2026, 16:01 UTC

Acquisizioni, Fusioni, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 giu 2026, 15:58 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 giu 2026, 15:58 UTC

Discorsi di Mercato

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 giu 2026, 15:55 UTC

Discorsi di Mercato

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 giu 2026, 15:41 UTC

Discorsi di Mercato

Gold Falls Below 200-Day Moving Average -- Market Talk

Confronto tra pari

Modifica del prezzo

Incyte Corp Previsione

Obiettivo di Prezzo

By TipRanks

6.27% in crescita

Previsioni per 12 mesi

Media 108.8 USD 6.27%

Alto 135 USD

Basso 75 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Incyte Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

18 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 18 che hanno fornito valutazioni azionarie a Incyte Corp - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

151 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation